Inamed augments PMA filing
This article was originally published in The Gray Sheet
Supplemental data for firm's silicone gel-filled breast implants have been submitted to FDA, company announces Aug. 19. The addition responds to a January FDA non-approvable letter (1"The Gray Sheet" Jan. 12, 2004, p. 3). Inamed also has filed seven-year follow-up data on saline implants, required as a condition of May 2000 PMA approval, according to an Aug. 12 release (2"The Gray Sheet" May 15, 2000, p. 15). The data found a 9.8% deflation rate for the 876-patient augmentation cohort and 12.4% deflation for the 194-patient reconstruction cohort...
You may also be interested in...
Firms seeking premarket approval for silicone breast implants should conduct tests designed to more closely predict rupture and gel bleed under real-world conditions, according to new FDA draft guidelines
Informed consent labeling for saline-filled breast implants notes that 13-40% of women who receive the implants require some form of additional surgical treatment within three years.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.